Author

Evangelia Matenoglou

Albert Einstein College of MedicineORCID 0000-0001-9731-6703Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Ana Orive-RamosiD· 2 shared Beau BaarsiD· 2 shared Bijaya GaireiD· 2 shared Evripidis GavathiotisiD· 2 shared Mathieu DesaunayiD· 2 shared Poulikos I. PoulikakosiD· 2 shared Stuart A. AaronsoniD· 2 shared Christos AdamopoulosiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Ana Orive-RamosORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintOct 6, 2026

Binding kinetics enable tumor-selective MAPK and growth suppression by a Type 1 RAF Inhibitor

Mathieu Desaunay, Tara Peters, Evangelia Matenoglou…·Poulikos I. Poulikakos

This study identifies ELV-3111, a Type 1 RAF inhibitor that selectively suppresses MAPK and tumor growth by exploiting distinct binding kinetics, showing efficacy in RAS-mutant and BRAF-mutant models.

DOI 10.64898/2026.10.05.756774

humanexperimental assay

𝕏 PostBluesky

Cancer BiologyCancer DiscoveryPeer-reviewedSep 29, 2026

Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition

Ana Orive-Ramos, Bijaya Gaire, Christos Adamopoulos…·Poulikos I. Poulikakos

The paper shows RAF/MEK glues enable full-dose combination with pan-RAF inhibitors, enhancing tumor-selective MAPK inhibition and tumor regression in RAS-mutant models.

DOI 10.1158/2159-8290.cd-25-1596

humanproteomics

𝕏 PostBluesky